Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Ann Surg Oncol. 2023 Jun 16;30(9):5327–5328. doi: 10.1245/s10434-023-13749-0

TABLE 1.

Reporting of MSLT-II criteria and clinically actionable recommendations in melanoma nodal surveillance ultrasonography

Variable Normal ultrasound [n = 215] Abnormal ultrasound [n = 54] Total [N = 269] p-Value
MSLT-II criteria reported
  0 182 (84.7) 6 (11.1) 188 (69.9) < 0.0001
  1 28 (13.0) 20 (37.0) 48 (17.8)
  2 2 (1.0) 15 (27.8) 17 (6.3)
  3 3 (1.4) 13 (24.1) 16 (6.0)
Clinically actionable recommendation made
  Continue surveillance 204 (94.9) 27 (50.0) 231 (85.9) < 0.0001
  Biopsy 0 (0.0) 8 (14.8) 8 (2.9)
  Combined 204 (94.9) 35 (64.8) 239 (88.8)

Variables are expressed as frequency (%)

MSLT-II Second Multicenter Selective Lymphadenectomy Trial